Integra LifeSciences (NASDAQ:IART) Hits New 52-Week High – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.92 and last traded at $18.7530, with a volume of 147081 shares changing hands. The stock had previously closed at $18.76.

Analyst Ratings Changes

IART has been the subject of several recent analyst reports. Truist Financial decreased their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $11.00 to $16.00 in a research report on Thursday, May 28th. Finally, Wells Fargo & Company lifted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $16.20.

Integra LifeSciences Stock Performance

The company has a market capitalization of $1.47 billion, a P/E ratio of -2.92, a PEG ratio of 1.30 and a beta of 1.24. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The stock has a fifty day simple moving average of $14.84 and a 200-day simple moving average of $12.52.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Several hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after acquiring an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Integra LifeSciences during the first quarter worth about $277,000. Goldman Sachs Group Inc. grew its position in shares of Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after purchasing an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Integra LifeSciences in the second quarter valued at approximately $491,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.